Cargando…
COVID-19 Vaccination in Fragile Patients: Current Evidence and an Harmonized Transdisease Trial
Patients diagnosed with malignancy, neurological and immunological disorders, i.e., fragile patients, have been excluded from COVID-19 vaccine trials. However, this population may present immune response abnormalities, and relative reduced vaccine responsiveness. Here we review the limited current e...
| Autores principales: | , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8383886/ https://www.ncbi.nlm.nih.gov/pubmed/34447374 http://dx.doi.org/10.3389/fimmu.2021.704110 |
| _version_ | 1783741823740542976 |
|---|---|
| author | Agrati, Chiara Di Cosimo, Serena Fenoglio, Daniela Apolone, Giovanni Ciceri, Fabio Ciliberto, Gennaro Baldanti, Fausto Costantini, Massimo Giannarelli, Diana Ippolito, Giuseppe Locatelli, Franco Mantovani, Alberto Morrone, Aldo Tagliavini, Fabrizio Uccelli, Antonio Zinzani, Pier Luigi Silvestris, Nicola Rescigno, Maria |
| author_facet | Agrati, Chiara Di Cosimo, Serena Fenoglio, Daniela Apolone, Giovanni Ciceri, Fabio Ciliberto, Gennaro Baldanti, Fausto Costantini, Massimo Giannarelli, Diana Ippolito, Giuseppe Locatelli, Franco Mantovani, Alberto Morrone, Aldo Tagliavini, Fabrizio Uccelli, Antonio Zinzani, Pier Luigi Silvestris, Nicola Rescigno, Maria |
| author_sort | Agrati, Chiara |
| collection | PubMed |
| description | Patients diagnosed with malignancy, neurological and immunological disorders, i.e., fragile patients, have been excluded from COVID-19 vaccine trials. However, this population may present immune response abnormalities, and relative reduced vaccine responsiveness. Here we review the limited current evidence on the immune responses to vaccination of patients with different underlying diseases. To address open questions we present the VAX4FRAIL study aimed at assessing immune responses to vaccination in a large transdisease cohort of patients with cancer, neurological and rheumatological diseases. |
| format | Online Article Text |
| id | pubmed-8383886 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Frontiers Media S.A. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-83838862021-08-25 COVID-19 Vaccination in Fragile Patients: Current Evidence and an Harmonized Transdisease Trial Agrati, Chiara Di Cosimo, Serena Fenoglio, Daniela Apolone, Giovanni Ciceri, Fabio Ciliberto, Gennaro Baldanti, Fausto Costantini, Massimo Giannarelli, Diana Ippolito, Giuseppe Locatelli, Franco Mantovani, Alberto Morrone, Aldo Tagliavini, Fabrizio Uccelli, Antonio Zinzani, Pier Luigi Silvestris, Nicola Rescigno, Maria Front Immunol Immunology Patients diagnosed with malignancy, neurological and immunological disorders, i.e., fragile patients, have been excluded from COVID-19 vaccine trials. However, this population may present immune response abnormalities, and relative reduced vaccine responsiveness. Here we review the limited current evidence on the immune responses to vaccination of patients with different underlying diseases. To address open questions we present the VAX4FRAIL study aimed at assessing immune responses to vaccination in a large transdisease cohort of patients with cancer, neurological and rheumatological diseases. Frontiers Media S.A. 2021-08-10 /pmc/articles/PMC8383886/ /pubmed/34447374 http://dx.doi.org/10.3389/fimmu.2021.704110 Text en Copyright © 2021 Agrati, Di Cosimo, Fenoglio, Apolone, Ciceri, Ciliberto, Baldanti, Costantini, Giannarelli, Ippolito, Locatelli, Mantovani, Morrone, Tagliavini, Uccelli, Zinzani, Silvestris and Rescigno https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| spellingShingle | Immunology Agrati, Chiara Di Cosimo, Serena Fenoglio, Daniela Apolone, Giovanni Ciceri, Fabio Ciliberto, Gennaro Baldanti, Fausto Costantini, Massimo Giannarelli, Diana Ippolito, Giuseppe Locatelli, Franco Mantovani, Alberto Morrone, Aldo Tagliavini, Fabrizio Uccelli, Antonio Zinzani, Pier Luigi Silvestris, Nicola Rescigno, Maria COVID-19 Vaccination in Fragile Patients: Current Evidence and an Harmonized Transdisease Trial |
| title | COVID-19 Vaccination in Fragile Patients: Current Evidence and an Harmonized Transdisease Trial |
| title_full | COVID-19 Vaccination in Fragile Patients: Current Evidence and an Harmonized Transdisease Trial |
| title_fullStr | COVID-19 Vaccination in Fragile Patients: Current Evidence and an Harmonized Transdisease Trial |
| title_full_unstemmed | COVID-19 Vaccination in Fragile Patients: Current Evidence and an Harmonized Transdisease Trial |
| title_short | COVID-19 Vaccination in Fragile Patients: Current Evidence and an Harmonized Transdisease Trial |
| title_sort | covid-19 vaccination in fragile patients: current evidence and an harmonized transdisease trial |
| topic | Immunology |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8383886/ https://www.ncbi.nlm.nih.gov/pubmed/34447374 http://dx.doi.org/10.3389/fimmu.2021.704110 |
| work_keys_str_mv | AT agratichiara covid19vaccinationinfragilepatientscurrentevidenceandanharmonizedtransdiseasetrial AT dicosimoserena covid19vaccinationinfragilepatientscurrentevidenceandanharmonizedtransdiseasetrial AT fenogliodaniela covid19vaccinationinfragilepatientscurrentevidenceandanharmonizedtransdiseasetrial AT apolonegiovanni covid19vaccinationinfragilepatientscurrentevidenceandanharmonizedtransdiseasetrial AT cicerifabio covid19vaccinationinfragilepatientscurrentevidenceandanharmonizedtransdiseasetrial AT cilibertogennaro covid19vaccinationinfragilepatientscurrentevidenceandanharmonizedtransdiseasetrial AT baldantifausto covid19vaccinationinfragilepatientscurrentevidenceandanharmonizedtransdiseasetrial AT costantinimassimo covid19vaccinationinfragilepatientscurrentevidenceandanharmonizedtransdiseasetrial AT giannarellidiana covid19vaccinationinfragilepatientscurrentevidenceandanharmonizedtransdiseasetrial AT ippolitogiuseppe covid19vaccinationinfragilepatientscurrentevidenceandanharmonizedtransdiseasetrial AT locatellifranco covid19vaccinationinfragilepatientscurrentevidenceandanharmonizedtransdiseasetrial AT mantovanialberto covid19vaccinationinfragilepatientscurrentevidenceandanharmonizedtransdiseasetrial AT morronealdo covid19vaccinationinfragilepatientscurrentevidenceandanharmonizedtransdiseasetrial AT tagliavinifabrizio covid19vaccinationinfragilepatientscurrentevidenceandanharmonizedtransdiseasetrial AT uccelliantonio covid19vaccinationinfragilepatientscurrentevidenceandanharmonizedtransdiseasetrial AT zinzanipierluigi covid19vaccinationinfragilepatientscurrentevidenceandanharmonizedtransdiseasetrial AT silvestrisnicola covid19vaccinationinfragilepatientscurrentevidenceandanharmonizedtransdiseasetrial AT rescignomaria covid19vaccinationinfragilepatientscurrentevidenceandanharmonizedtransdiseasetrial |